Development of investigational radiation modifiers

Journal of the National Cancer Institute

Volumn 95, Issue 9, 2003, Pages 646-651

  Colevas, A Dimitrios ^a   Brown, J Martin ^b   Hahn, Stephen ^f   Mitchell, James ^a   Camphausen, Kevin ^a   Coleman, C Norman ^a   Conley, Barbara ^a   Cumberlin, Richard ^a   Stone, Helen B ^a   Wong, Rosemary ^a   Freidlin, Boris ^a   Kobayashi, Ken ^a   Murgo, Anthony J ^a   Shoemaker, Robert ^a   Tofilon, Philip J ^a   Choy, Hak ^c   Dicker, Adam ^m   Doroshow, James H ^m   Formenti, Silvia C ^d   Garden, Adam ^e   Gately, Stephen ^m   Hill, Richard ^g   Kinsella, Timothy J ^h   Moore, Malcolm ^m   Sarkaria, Jann ^m   Siemann, Dietmar ⁱ   Sokol, Gerald ^m   Teicher, Beverly A ^m   Trotti, Andy ^m   Turrisi III, Andrew T ^j   Urtasun, Raul ^k   Vokes, Everett ^l   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g UNIVERSITY OF TORONTO   (Canada)

^h CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF FLORIDA   (United States)

^j UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF ALBERTA   (Canada)

^l UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^m NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANTINEOPLASTIC AGENT; CISPLATIN; DNA BASE; ETANIDAZOLE; FLUOROURACIL; PYRIMIDINE DERIVATIVE; RADIOSENSITIZING AGENT; TAXANE DERIVATIVE; THYMIDYLATE SYNTHASE INHIBITOR; TIRAPAZAMINE; TRYPAN BLUE;

ARTICLE; BIOASSAY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL STUDY; CLINICAL TRIAL; CORRELATION FUNCTION; DATA ANALYSIS; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SPECIFICITY; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LD 50; NONHUMAN; PATIENT CARE; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIZATION; SIDE EFFECT; SOLID TUMOR; STANDARD; TUMOR CELL; TUMOR MODEL;

EID: 0038363472     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/95.9.646     Document Type: Article

References (29)

1. Peters WA 3rd, Liu PY, Barrett RJ 2nd, Stock RJ, Monk BJ, Berek JS, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000;18:1606-13.
2. Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler WC Jr., et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 1999; 17:1339-48.
3. Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL 3rd, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999;340:1154-61.
4. Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999;340: 1137-43.
5. National Cancer Institute. Cancer Therapy Evaluation Program mission statement. Available at: http://ctep.cancer.gov/about/mission.html. [Last accessed: 2/25/03].
6. Rasey JS, Krohn KA, Menard TW, Spence AM. Comparative biodistribution and radioprotection studies with three radioprotective drugs in mouse tumors. Int J Radiat Oncol Biol Phys 1986;12:1487-90.
7. Kinsella TJ, Mitchell JB, Russo A, Morstyn G, Glatstein E. The use of halogenated thymidine analogs as clinical radiosensitizers: rationale, current status, and future prospects: non-hypoxic cell sensitizers. Int J Radiat Oncol Biol Phys 1984;10:1399-406.
8. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998;58:1408-16.
9. Brown JM. Cell status - dead or alive? Nat Med 1996;2:1055-6:
10. Aldridge DR, Arends MJ, Radford IR. Increasing the susceptibility of the rat 208F fibroblast cell line to radiation-induced apoptosis does not alter its clonogenic survival dose-response. Br J Cancer 1995;71:571-7.
11. Han JW, Dionne CA, Kedersha NL, Goldmacher VS. p53 status affects the rate of the onset but not the overall extent of doxorubicin-induced cell death in rat-1 fibroblasts constitutively expressing c-Myc. Cancer Res 1997;57: 176-82.
12. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 1999;104:263-9.
13. Roninson IB, Broude EV, Chang BD. If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist Updat 2001;4:303-13.
14. Wouters BG, Giaccia AJ, Denko NC, Brown JM. Loss of p21Waf1/Cip1 sensitizes tumors to radiation by an apoptosis-independent mechanism. Cancer Res 1997;57:4703-6.
15. Yin DX, Schimke RT. BCL-2 expression delays drug-induced apoptosis but does not increase clonogenic survival after drug treatment in HeLa cells. Cancer Res 1995;55:4922-8.
16. Hamburger A, Salmon SE. Primary bioassay of human myeloma stem cells. J Clin Invest 1977;60:846-54.
17. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987;47:936-42.
18. Price P, McMillan TJ. Use of the tetrazolium assay in measuring the response of human tumor cells to ionizing radiation. Cancer Res 1990;50: 1392-6.
19. Kallman RF. Rodent tumor models in experimental cancer therapy. New York (NY): Pergamon Press; 1987.
20. Teicher BE. Tumor models in cancer research. Ottowa, Ontario, Canada: Humana Press; 2002.
21. Hill RP, Bush RS. A lung-colony assay to determine the radiosensitivity of cells of a solid tumour. Int J Radiat Biol Relat Stud Phys Chem Med 1969;15:435-44.
22. Begg A. Principles and practice of the tumor growth delay assay. In: Kallman R, editor. Rodent tumor models in experimental cancer therapy. New York (NY): Pergammon Press; 1987. p. 114-21.
23. Suit H, Sedlacek R, Thames H. Radiation dose-response assays of tumor control. In: Kallman R, editor. Rodent tumor models in experimental cancer therapy. New York (NY): Pergamon Press; 1987. p. 138-48.
24. Myers JN, Holsinger FC, Jasser SA, Bekele BN, Fidler IJ. An orthotopic nude mouse model of oral tongue squamous cell carcinoma. Clin Cancer Res 2002;8:293-8.
25. Steel GG, Peckham MJ. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 1979;5:85-91.
26. Chou T, Rideout D. Synergism and antagonism in chemotherapy. New York (NY): Academic Press; 1991.
27. Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC. Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 1997;89:1138-47.
28. Storer BE. Design and analysis of phase I clinical trials. Biometrics 1989; 45:925-37.
29. Kies MS, Haraf DJ, Rosen F, Stenson K, List M, Brockstein B, et al. Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer. J Clin Oncol 2001;19:1961-9.